PEG-MGF
PEGylated mechano growth factor
PEG-MGF is a PEGylated version of a peptide derived from mechano growth factor, an IGF-1 splice variant produced by muscle after damage.
Regulatory status: Not a medicine. No human trial of the PEGylated form has been published, and it is not approved anywhere.
Default vial
2 mg
Default mix
2 mL
Reported range
No published human dose
Draw (U-100)
20 u
A PEGylated version of a peptide derived from an IGF-1 splice variant. The PEGylated form studied in community protocols has no published human research of its own.
Where these numbers come from
No published study reports a dose for this compound in people. The figures here exist only so the calculator can run — they are not a recommendation. No published study tests the PEGylated form in people.
Reviewed October 2026
What it is
- Based on the C-terminal portion of IGF-1Ec, a splice variant of IGF-1 that muscle produces in response to mechanical stress.
- PEGylated — a polyethylene glycol chain is attached to slow clearance and extend its presence in the blood.
- The natural splice variant is a local, short-lived signal; the PEGylated form is designed to be neither.
- Sold as a research compound.
How it is described to act
- 1
No human pharmacokinetic data is published for the PEGylated form.
- 2
PEGylation is a well-established way to extend half-life, and that is its purpose here.
- 3
The underlying peptide is proposed to act on muscle satellite cells, prompting them to proliferate after damage.
- 4
No outcome has been measured in a published human study.
What the research has looked at
What exists and what does not
- Mechano growth factor itself, as a natural IGF-1 splice variant, has a real research literature in muscle biology.
- Pep-Tidy has not identified a published human study of the PEGylated synthetic peptide sold under this name. Rather than attach the splice-variant literature to it, this entry says so.
- The distinction matters: a natural local signal and a long-acting PEGylated analogue of a fragment of it are not the same thing.
Strength of evidence: Preclinical evidence only
No published human study tests this compound. The biology it is named after is real; the evidence that this version does anything in a person is not there.
What is published comes from cell and animal studies. Findings in those models frequently do not carry over to people.
Reported cautions and unknowns
- There is no human safety data.
- Extending the half-life of a signal the body produces locally and briefly changes what that signal is, and the consequences have not been studied.
- PEGylation itself raises questions about accumulation that have been studied for approved PEGylated drugs but not for this one.
References
There are none. A search of the published literature returns no studies of this compound — no human trials, no animal work, no cell studies. Anything claimed about it elsewhere is not drawn from published research on this molecule.
Handling this vial
- Lyophilized vials are generally stored at 2–8 °C and kept out of light; once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after 28 days.
- Mix by aiming water down the vial wall and rolling gently — do not shake — and never re-freeze a reconstituted vial.
- Pep-Tidy cannot verify what is in your vial. Ask your supplier for a current Certificate of Analysis (HPLC/MS).
PEG-MGF questions people ask
How do you reconstitute PEG-MGF?
A common starting point for a 2 mg vial of PEG-MGF is 2 mL of bacteriostatic water, which gives 1 mg per mL. Aim the water down the inside wall of the vial, let it dissolve on its own, and roll gently instead of shaking. Pep-Tidy's reconstitution calculator will recalculate the numbers for any other vial size or water volume you use.
How many units of PEG-MGF is one dose?
At 1 mg per mL, that works out to about 20 units on a U-100 insulin syringe for a 200 mcg dose. Change the vial size, water volume, or target dose in the calculator and the syringe reading updates with it. This is arithmetic, not a dosing recommendation.
What dosing schedule is reported for PEG-MGF?
Published and community sources describe No published human dose, subcutaneous, twice weekly, typically run 4 weeks on and 4 weeks off. These figures describe what has been reported, not what anyone should take — talk to a licensed clinician first.
How should PEG-MGF be stored?
Lyophilized PEG-MGF vials are generally kept at 2–8 °C and out of light. Once reconstituted with bacteriostatic water they are refrigerated and commonly discarded after about 28 days. Never re-freeze a reconstituted vial and never shake it.
Read this before you act on anything above
Everything on this page is a summary of what other people have published — it is not medical advice, not a recommendation, and not a dosing instruction. Reported dose ranges describe what appears in the literature or in community protocols, not what anyone should take. Talk to a licensed clinician before using any peptide.